Making PIN and Telehealth Work Together—It Can Be Done

panelists at the JP Morgan investors conference observed that pharma no longer follows a path of establishing a presence in one tumor type before moving to the next-today's news is all about targets, regardless of where cancer emerges. 1 This approach, Hahn said, relies on patients receiving timely diagnostic testing.However, he described the testing arena as "a bit of a mess right now." 1 Cutting-edge tools used at academic centers, such as Hahn's former employer The University of Texas MD Anderson Cancer Center, may not be available in a community clinic.Advances in diagnostics, used to catch cancer as early as possible, and the use of biomarkers, to guide treatment, have reached patients at highly uneven rates.Alongside Hahn on the panel was Dan Malarek, PhD, who is CEO of Foundation Medicine; he previewed the company's FoundationOne Monitor assay, a blood test that will measure circulating tumor DNA (ctDNA) for both responses and resistance to therapy. 2 Meanwhile, panel moderator John Carroll of Endpoints News, a cancer survivor, said he's had tests that have been in use for 50 years.More than 5 years ago, the American Society of Clinical Oncology (ASCO) warned that the rise of precision medicine, in which genomic tests drive personalized approaches, matching treatments with PRECISION MEDICINE